TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03211819

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immediate implant placement
Description: A prophylactic antibiotic(Flumox 500mg, Egyptian Int. Pharmaceutical Industries Co.,A.R.E.) would be given to the patient 3 days prior to the surgery. Then on the day of surgery, (AK) will extract the remaining root or tooth in an atraumatic procedure using lancet, periotome (Nordent Manufacturing Inc. U.S.A), minimal force and rotational movement.~After extraction the socket will be examined for intact labial and palatal bone using depth probe. If all walls are intact the socket would be eligible for immediate implant placement.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: immediate implant placement
Description: A prophylactic antibiotic(Flumox 500mg, Egyptian Int. Pharmaceutical Industries Co.,A.R.E.) would be given to the patient 3 days prior to the surgery. Then on the day of surgery, (AK) will extract the remaining root or tooth in an atraumatic procedure using lancet, periotome (Nordent Manufacturing Inc. U.S.A), minimal force and rotational movement.~After extraction the socket will be examined for intact labial and palatal bone using depth probe. If all walls are intact the socket would be eligible for immediate implant placement.
Study: NCT01683136

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HBDL-coil Repetitive Deep Transcranial magnetic stimulation (rdTMS)
Description: on the first day subjects will be randomized to receive sham stimulation or real stimulation. subject who received real stimulation on the first day will receive sham stimulation on the second day. Likewise, Subjects who received sham stimulation on the first day will receive real stimulation on the second day. After receiving stimulation subjects will perform a facemorph task which evaluates their empathic capabilities.~From the third treatment all subjects will recive a real stimulaitiobn: a session of rdTMS includes 4 cycles of 5 minutes of stimulation at a frequency of 10 Hz to the supplementary motor cortex and then a 20 seconds recess.each subject would undergo 5 sessions a week for 4 weeks

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: HBDL-coil Repetitive Deep Transcranial magnetic stimulation (rdTMS)
Description: on the first day subjects will be randomized to receive sham stimulation or real stimulation. subject who received real stimulation on the first day will receive sham stimulation on the second day. Likewise, Subjects who received sham stimulation on the first day will receive real stimulation on the second day. After receiving stimulation subjects will perform a facemorph task which evaluates their empathic capabilities.~From the third treatment all subjects will recive a real stimulaitiobn: a session of rdTMS includes 4 cycles of 5 minutes of stimulation at a frequency of 10 Hz to the supplementary motor cortex and then a 20 seconds recess.each subject would undergo 5 sessions a week for 4 weeks
Study: NCT03584048

Intervention type: OTHER
Intervention: Alert to provider
Description: Providers receive alerts of sub-optimal patient attendance using 4 rules.
Study: NCT03134391

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vapocoolant spray, EMLA
Description: Subjects were given vapocoolant spray to reduce pain from spinal injection; subjects were given EMLA to reduce pain from spinal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vapocoolant spray, EMLA
Description: Subjects were given vapocoolant spray to reduce pain from spinal injection; subjects were given EMLA to reduce pain from spinal injection
Study: NCT03375086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX3330
Description: APX3330 will be supplied as 60 and 120 mg orally administered tablets. Patients will receive a fixed dose of APX3330 twice daily (i.e., bid) each day of a 21-day cycle. The starting dose of APX3330 will be a daily dose of 240 mg (i.e., 120 mg/dose bid). Doses will be increased until identification of a maximum tolerated dose or bio-effective dose, whichever is lower.
Study: NCT00682929

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled Cannabis
Description: Participants will be instructed to smoke one cannabis cigarette, daily for 7 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral THC
Description: Participants will be instructed to take two 5 mg dronabinol tablets two hours prior to the inhaled medication, daily for 7 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Placebo
Description: Participants will be instructed to take two placebo tablets two hours prior to the inhaled medication, daily for 7 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo
Description: Participants will be instructed to take two placebo tablets two hours prior to the inhaled medication, daily for 7 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled placebo
Description: Participants will be instructed to smoke one placebo cigarette, daily for 7 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled placebo
Description: Participants will be instructed to smoke one placebo cigarette, daily for 7 weeks.
Study: NCT02458677

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02382653

Intervention type: DRUG
Group type: OTHER
Intervention: oral perixicam
Description: Oral adminstration of buccal perixicam
Study: NCT05521971

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multifaceted pharmacist-led intervention
Description: * Educational sessions were provided to the physicians and nursing staff.~* Discontinuation regimens were developed. Prescribers were free to choose whether or not to actually use them. The regimens were derived from the regimen used by Petrovic et al. and encouraged a switch from any benzodiazepine to lorazepam 1 mg OD for one week followed by drug stop. Z-drugs were switched to zolpidem 5 mg OD for one week followed by drug stop. If deemed necessary, a pro re nata regimen of lorazepam 1 mg or zolpidem 5 mg for one additional week was prescribed respectively. The discontinuation regimens were incorporated into the hospital's electronic prescribing system. Furthermore, a clinical decision support system provided additional support.~* Patient education sessions were provided upon enrolment and at discharge. Specific patient leaflets were used to facilitate patient education.~* The patient's primary care physician and, if applicable, the nursing home were informed by phone.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care group
Description: all patients received comprehensive geriatric care without any systematic clinical pharmacist involvement regarding deprescribing of hypnotics. Treating physicians were not actively informed on the patient's participation in this particular study.
Study: NCT00607126

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat
Description: locomotor training using body weight support on a treadmill

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: resistive training
Description: resistive training using theraband and/or weights
Study: NCT01062009

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zinc sulfate
Description: Zinc sulfate 200 mcg/ml in Normal Saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zinc sulfate
Description: Zinc sulfate 200 mcg/ml in Normal Saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zinc sulfate
Description: Zinc sulfate 200 mcg/ml in Normal Saline
Study: NCT00856986

Intervention type: DRUG
Group type: OTHER
Intervention: liraglutide
Description: Liraglutide 1.8 mg/day for subcutaneous (under the skin) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Liraglutide 1.8 mg/day for subcutaneous (under the skin) injection.

Intervention type: DRUG
Group type: OTHER
Intervention: liraglutide
Description: Liraglutide 1.8 mg/day for subcutaneous (under the skin) injection.
Study: NCT02297815

Intervention type: DRUG
Intervention: Broad-spectrum antibiotics
Description: Amoxicillin-clavulanate, azithromycin, cefdinir, cefprozil, cefuroxime axetil, cefadroxil, cephalexin

Intervention type: DRUG
Intervention: Narrow-spectrum antibiotics
Description: Amoxicillin, Penicillin
Study: NCT01224327

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord Mesenchymal Stem Cells
Description: Umbilical cord mesenchymal stem cells were infused to patients using interventional method via hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography,umbilical cord MSCs were infused slowly for 15-20minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conserved therapy
Description: Oral or intravenous administration
Study: NCT02373046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX4211
Description: Single dose of LX4211 400 mg as 1 × 400-mg tablet Day 1 or Day 9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX4211
Description: Single dose of LX4211 400 mg as 1 × 400-mg tablet Day 1 or Day 9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX4211
Description: Single dose of LX4211 400 mg as 2 × 200-mg tablets on Day 1 or Day 9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX4211
Description: Single dose of LX4211 400 mg as 2 × 200-mg tablets on Day 1 or Day 9
Study: NCT03621072

Intervention type: DRUG
Group type: OTHER
Intervention: Fluconazole 150mg Capsule Originator
Description: 150mg fluconazole capsule (originator) manufactured at Pfizer Fareva, Amboise, France

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole 150mg Capsule Localized Originator
Description: 150mg Fluconazole capsule (localized originator) manufactured at Pfizer, Dalian, China
Study: NCT04012827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate, doxorubicin, ifosfamide
Description: Doxorubicin 50mg/m2 d1 , Ifosfamide 2.5g/m2 d1-3 , Apatinib mesylate 375mg qd
Study: NCT03665766

Intervention type: DRUG
Intervention: Cycloserine,Tacrolimus

Intervention type: DRUG
Intervention: Cycloserine,Tacrolimus

Intervention type: DRUG
Intervention: Cycloserine,Tacrolimus

Intervention type: DRUG
Intervention: Cycloserine,Tacrolimus

Intervention type: DRUG
Intervention: Cycloserine,Tacrolimus

Intervention type: DRUG
Intervention: Cycloserine,Tacrolimus
Study: NCT03026296

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Life Center
Description: Depending on what behavior participants aim to change, they get individual counselling using elements from motivational interviewing, group-based exercise twice a week, diet courses and tobacco secession courses during three months
Study: NCT00252512

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Participants complete urine and breath screens 2 times per week for 8 weeks. If urine and breath screens are both negative, the participant receives a chance to draw tokens from a bowl. Some tokens are social reinforcement (Good Job!). Other have monetary value.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants complete urine and breath screens 2 times per week for 8 weeks with no reinforcement for negative results.
Study: NCT01007188

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1.5PD almonds
Description: average American diet plus 1.5 oz per day almonds

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3.0PD almonds
Description: average American diet plus 3.0 oz per day almonds

Intervention type: OTHER
Group type: OTHER
Intervention: Base (without almonds)
Description: average American diet without almonds
Study: NCT02014259

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: semaglutide
Description: Once daily oral administration of semaglutide formulated with SNAC. Dose escalation, with 5 days on 5 mg followed by 5 days on 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Once daily oral administration of semaglutide formulated with SNAC. Dose escalation, with 5 days on 5 mg followed by 5 days on 10 mg
Study: NCT03965104

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypertension Canada Professional Certification Program: HC-PCP
Description: The HC-PCP is a certification program which aims to provide training to generalist primary care providers in the screening, prevention, and management of hypertension.The competencies assessed in the program have been validated for their importance through a national survey of hypertension experts and primary care providers.
Study: NCT03181971

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Water First
Description: The Water First intervention consists of increased access to safe and appealing drinking water in schools, school-wide promotion to increase students' intake of water, and education directed to 4th grade students and their families to increase intake of water.
Study: NCT01564251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0575
Description: Participants will receive GDC-0575 orally at a starting dose of 15 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0575
Description: Participants will receive GDC-0575 orally at a starting dose of 15 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0575
Description: Participants will receive GDC-0575 orally at a starting dose of 15 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0575
Description: Participants will receive GDC-0575 orally at a starting dose of 15 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Participants will receive gemcitabine intravenously at a dose of 1000 mg/m\^2 and/or 500 mg/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Participants will receive gemcitabine intravenously at a dose of 1000 mg/m\^2 and/or 500 mg/m\^2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Participants will receive gemcitabine intravenously at a dose of 1000 mg/m\^2 and/or 500 mg/m\^2.
Study: NCT01229683

Intervention type: PROCEDURE
Intervention: Interscalene Nerve Block
Description: Patients undergoing shoulder surgery will be given an Interscalene Nerve Block. The patients' strength and sensation in their hand and forearm will be tested to determine if the nerve block is affectively delivering anesthetic to the nerves that serve these areas.
Study: NCT03937388

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cochlear stimulation strategy including time-fixed gaps
Description: Investigation of the impact of time-fixed gaps (zero-stimulation periods) in the cochlear stimulation strategy on speech performance and hearing quality.
Study: NCT04660695

Intervention type: DEVICE
Intervention: EUS-guided gastroenterostomy
Description: Firstly, un upper digestive endoscopy is performed with a conventional gastroscope. A guidewire is passed through the malignant lesion causing the gastric outlet obstruction. Once the guidewire is located in the distal duodenum/proximal jejunum, a nasobiliary drain (Nasal Biliary Drainage Sets, Cook medical, Indiana) is advanced over the guidewire until its distal end is placed in the distal duodenum/jejunum. At this point the gastroscope is substituted by a therapeutic echoendoscope. With the echoendoscope in place, the target bowel loop is filled with saline combined with methilene blue and radiopaque contrast. The echoendoscope is used to identify the target bowel loop. AFter identifying the target, a lumen apposing metal stent (Axios, Boston Scientific, Massachusetts) is deployed across the gastric and bowel using its electrocautery enhanced deployment device.
Study: NCT01048242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rozerem
Description: Ramelteon (rozerem) 8mg oral before bedtime

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT04454346

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double Foley Catheter For Ripening The Unfavorable Cervix
Description: New method

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double Foley Catheter For Ripening The Unfavorable Cervix
Description: New method

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double Foley Catheter For Ripening The Unfavorable Cervix
Description: New method
Study: NCT00109213

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Laminectomy with Instrumented Pedicle Screw Fusion
Description: Removal of bone to decompress spinal nerves with placement of spinal screws and extra bone to strengthen the spine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Laminectomy
Description: Removal of bone to decompress spinal nerves
Study: NCT02364037

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CHOICE Project Structured Contraceptive Counseling
Description: Women in both phases of the study will receive the structured contraceptive counseling developed by the Contraceptive CHOICE Project.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CHOICE Project Structured Contraceptive Counseling
Description: Women in both phases of the study will receive the structured contraceptive counseling developed by the Contraceptive CHOICE Project.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Contraceptive Education Session
Description: Prior to Phase 2, health care providers at the recruitment sites will undergo a contraceptive education session with a focus on evidence-based provision of contraception including LARC (IUDs and implant) and same-day insertion.

Intervention type: DEVICE
Group type: OTHER
Intervention: Cost Support for IUDs and implants
Description: Women in Phase 2 of the study who desire an IUD or implant can receive one through the study at no cost if they do not have insurance coverage. If women have insurance that covers the device, her insurance will be billed for the cost of the device.
Study: NCT01384565

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF+EPO
Description: Drug: Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO)~G-CSF (in prefilled syringe) at a dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Darbopoetin alpha 100 mcg/ week (in prefilled syringe) for 4 weeks (total 4 doses).~Arms: G-CSF+EPO Drug: Placebo~Placebo 1 (in prefilled syringe) s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Placebo 2 every week (in prefilled syringe) for 4 weeks (total 4 doses).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 (in prefilled syringe) s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Placebo 2 every week (in prefilled syringe) for 4 weeks (total 4 doses).
Study: NCT00856986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Liraglutide 1.8 mg/day for subcutaneous (under the skin) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Liraglutide 1.8 mg/day for subcutaneous (under the skin) injection.
Study: NCT00816491

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional white light colonoscopy
Description: conventional white light colonoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FICE (Fujinon Intelligent Chromoendoscopy)
Description: chromoendoscopy
Study: NCT03293355

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VPN
Description: Two in-person sessions will take place one week apart for the VPN intervention targeting CHW. The intervention contents aim to utilize traditional communications tools and the latest technology to tackle challenges faced by service providers working in commune health centers and the impact of these challenges on their patients' treatment initiation, retention, and adherence. In addition, booster sessions will be offered once every month during the first three months and once every three months thereafter. The booster sessions will focus on participants' reports of their experiences, reinforcement of efforts, and continued skill building for problem solving.
Study: NCT04120246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha-tocopheryloxyacetic Acid
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV
Study: NCT03109743

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sisters-GPS: Group Clinical Visits
Description: Sisters-GPS will be involve group clinical visits where by the same group participants with meet with a clinician and behaviorist to receive education, self-management skills development, and clinical assessment over the seven weekly group visits. The content will focus specifically on HIV medications and medication adherence. Additionally, the intervention will involve a private social media website where participants will be able to engage with one another between group clinical visits. Participants will receive food and a roundtrip Metrocard at each group clinical visit.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control: One-on-one Adherence Counseling
Description: For participants in the control arm, the counselor will provide standard-of-care adherence counseling, which includes education about ARVs and the importance of adherence, and addressing non-adherence including assessment of psychosocial barriers to adherence. For visits to the adherence counselor, participants will receive round-trip MetroCards as per clinic policy. Control arm participants will be expected to attend a minimum of three visits with the adherence counselor.
Study: NCT04111796

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nature based solution for stress reduction
Description: participation in nature activities: 30 min stress management in nature and group activity (walking, cycling)
Study: NCT00856986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Insulin detemir subcutaneous (under the skin) injection once daily. Dose will be titrated (individually adjusted) based on fasting self-measured plasma glucose levels according to a pre-specified algorithm

Intervention type: DRUG
Group type: OTHER
Intervention: insulin detemir
Description: Insulin detemir subcutaneous (under the skin) injection once daily. Dose will be titrated (individually adjusted) based on fasting self-measured plasma glucose levels according to a pre-specified algorithm

Intervention type: DRUG
Group type: OTHER
Intervention: metformin
Description: Metformin tablets, at least 1500 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Metformin tablets, at least 1500 mg/day

Intervention type: DRUG
Group type: OTHER
Intervention: metformin
Description: Metformin tablets, at least 1500 mg/day
Study: NCT01977196

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DPT/HepatitisB/Hib vaccine
Description: DPT/HepatitisB/Hib vaccine (Bio Farma)